Secular trends in cardiovascular mortality in Iran, with special reference to Isfahan. 1999

N Sarraf-Zadegan, and M Boshtam, and H Malekafzali, and N Bashardoost, and F A Sayed-Tabatabaei, and M Rafiei, and A Khalili, and S Mostafavi, and M Khami, and R Hassanvand
Isfahan Cardiovascular Research Center, Iran.

OBJECTIVE There has been a general decline in mortality from cardiovascular diseases (CVDs) in most of the developed countries since the beginning of the 1970s. Still, in recent years developing countries have seen an increasing frequency in CVD mortality. However, mortality rate studies in these populations are scarce. Here we report all-cause and CVD mortality rates for men and women aged 25-74 years over a 16-year period in 24 cities in Iran with special reference to the city of Isfahan. RESULTS The study was based on national death records using the ninth international classification of diseases and age standardization was performed using the total population of Iran in 1985 as a standard. Due to limitations in available data, mortality rates for the specific categories of CVD for the whole country could not be provided. The in-hospital death rates following myocardial infarction in coronary care units (CCUs) and cardiology departments in Isfahan hospitals were also assessed. The completed medical records from hospitals or the relatives of decedents were reviewed by physicians certified in internal medicine, cardiology and neurology to assess the reliability of death certificate data regarding CVD by determining the sensitivity and specificity of the death certificates against the standard of the reviewers. The official circulatory diseases proportional mortality ratio continues to rise since 1981 with a steep increase since 1987, constituting 26.6% and 47.3% of all deaths in 1981 and 1995, respectively. Age-adjusted all-cause and CVD mortality data were decreasing since 1981 and increasing since 1990. During those years age-adjusted CVD, stroke and other CVD mortality rates were decreasing in Isfahan with a slight increase in ischaemic heart disease (IHD) death rates in both sexes. Mortality rates based on sex showed a 38% and 24.8% decline in all-cause and CVD mortality in men between 1981 to 1995, and a 35% and 34.9% decline for female mortality rates for the same period, respectively. The in-hospital death rate following myocardial infarction in Isfahan was increasing between 1993 and 1995 with a slight decrease thereafter. The results of death certification assessment showed a specificity of 0.89 and a sensitivity of 0.43 with the positive and negative predictive values of 0.82 and 0.57, respectively. CONCLUSIONS These data indicate that circulatory diseases remain a serious public health threat in Iran. It suggests the ongoing need for more regular, systematic and innovative surveillance data to improve the capability of measuring, explaining and predicting the disease trend on which the national public health policy depends.

UI MeSH Term Description Entries
D007492 Iran A country bordering the Gulf of Oman, the Persian Gulf, and the Caspian Sea, between Iraq and Pakistan. The capital is Tehran. Islamic Republic of Iran
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011159 Population Surveillance Ongoing scrutiny of a population (general population, study population, target population, etc.), generally using methods distinguished by their practicability, uniformity, and frequently their rapidity, rather than by complete accuracy. Surveillance, Population
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

N Sarraf-Zadegan, and M Boshtam, and H Malekafzali, and N Bashardoost, and F A Sayed-Tabatabaei, and M Rafiei, and A Khalili, and S Mostafavi, and M Khami, and R Hassanvand
January 1970, Acta medica Scandinavica. Supplementum,
N Sarraf-Zadegan, and M Boshtam, and H Malekafzali, and N Bashardoost, and F A Sayed-Tabatabaei, and M Rafiei, and A Khalili, and S Mostafavi, and M Khami, and R Hassanvand
September 1982, JAMA,
N Sarraf-Zadegan, and M Boshtam, and H Malekafzali, and N Bashardoost, and F A Sayed-Tabatabaei, and M Rafiei, and A Khalili, and S Mostafavi, and M Khami, and R Hassanvand
January 2017, Journal of education and health promotion,
N Sarraf-Zadegan, and M Boshtam, and H Malekafzali, and N Bashardoost, and F A Sayed-Tabatabaei, and M Rafiei, and A Khalili, and S Mostafavi, and M Khami, and R Hassanvand
April 1969, Bulletin of the World Health Organization,
N Sarraf-Zadegan, and M Boshtam, and H Malekafzali, and N Bashardoost, and F A Sayed-Tabatabaei, and M Rafiei, and A Khalili, and S Mostafavi, and M Khami, and R Hassanvand
October 2002, Journal of human hypertension,
N Sarraf-Zadegan, and M Boshtam, and H Malekafzali, and N Bashardoost, and F A Sayed-Tabatabaei, and M Rafiei, and A Khalili, and S Mostafavi, and M Khami, and R Hassanvand
June 1994, Journal of human hypertension,
N Sarraf-Zadegan, and M Boshtam, and H Malekafzali, and N Bashardoost, and F A Sayed-Tabatabaei, and M Rafiei, and A Khalili, and S Mostafavi, and M Khami, and R Hassanvand
November 2019, ARYA atherosclerosis,
N Sarraf-Zadegan, and M Boshtam, and H Malekafzali, and N Bashardoost, and F A Sayed-Tabatabaei, and M Rafiei, and A Khalili, and S Mostafavi, and M Khami, and R Hassanvand
January 1995, Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)),
N Sarraf-Zadegan, and M Boshtam, and H Malekafzali, and N Bashardoost, and F A Sayed-Tabatabaei, and M Rafiei, and A Khalili, and S Mostafavi, and M Khami, and R Hassanvand
September 1974, Lancet (London, England),
N Sarraf-Zadegan, and M Boshtam, and H Malekafzali, and N Bashardoost, and F A Sayed-Tabatabaei, and M Rafiei, and A Khalili, and S Mostafavi, and M Khami, and R Hassanvand
October 1968, Nihon Shika Ishikai zasshi,
Copied contents to your clipboard!